Drugs / Disitamab Vedotin
Trials 13 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06016062 Background | Sep 2023 → Dec 2025 overdue | cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Disitamab Vedotin | “RC48 (Disitamab Vedotin) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate, with a novel humanized anti-HER2 antibody disitamab conjugated to...” NCT06574763 ↗ |
| Known as | R48-ADC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095273 ↗ |
| Known as | RC48 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06016062 ↗ |
| Known as | RC48+SOX+Sindilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06992362 ↗ |
| Modality | Other / unclassified | “The anti-HER2-ADC drug RC48 also achieved significant efficacy in HER2-overexpressed advanced urothelial carcinoma” NCT05957757 ↗ |
| Route | Intravenous | “2.5mg/kg by intravenous infusion” NCT05241899 ↗ |
| Target | ERBB2 | “RC48 [a HER2-targeted antibody-drug conjugate (ADC)]” PMID 41816563 ↗ Feb 2026 |